PDCD1 and nonpapillary renal cell carcinoma: The subsequent CheckMate 214 trial investigated dual immune checkpoint inhibition using a PD-1 inhibitor (nivolumab) and a CTLA-4 inhibitor (ipilimumab) compared to sunitinib in the first-line treatment of advanced ccRCC [18].